Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1170-1187

  Huang, Qinhua ^a   Johnson, Ted W ^a   Bailey, Simon ^a   Brooun, Alexei ^a   Bunker, Kevin D ^a   Burke, Benjamin J ^a   Collins, Michael R ^a   Cook, Andrew S ^a   Cui, J Jean ^a   Dack, Kevin N ^a   Deal, Judith G ^a   Deng, Ya Li ^a   Dinh, Dac ^a   Engstrom, Lars D ^a   He, Mingying ^a   Hoffman, Jacqui ^a   Hoffman, Robert L ^a   Johnson, Patrick S ^a   Kania, Robert S ^a   Lam, Hieu ^a   Lam, Justine L ^a   Le, Phuong T ^a   Li, Qiuhua ^a   Lingardo, Laura ^a   Liu, Wei ^a   Lu, Melissa West ^a   McTigue, Michele ^a   Palmer, Cynthia L ^a   Richardson, Paul F ^a   Sach, Neal W ^a   Shen, Hong ^a   Smeal, Tod ^a   Smith, Graham L ^a   Stewart, Albert E ^a   Timofeevski, Sergei ^a   Tsaparikos, Konstantinos ^a   Wang, Hui ^a   Zhu, Huichun ^a   Zhu, Jinjiang ^a   Zou, Helen Y ^a   Edwards, Martin P ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINE; CRIZOTINIB;

ANAPLASTIC LYMPHOMA KINASE GENE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; GENE; GENE MUTATION; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

DRUG RESISTANCE, NEOPLASM; HUMANS; POINT MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84896887502     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401805h     Document Type: Article

References (50)

1. Morris, S. W.; Naeve, C.; Mathew, P.; James, P. L.; Kirstein, M. N.; Cui, X.; Witte, D. P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene 1997, 14, 2175-2188
2. Bilsland, J. G.; Wheeldon, A.; Mead, A.; Znamenskiy, P.; Almond, S.; Waters, K. A.; Thakur, M.; Beaumont, V.; Bonnert, T. P.; Heavens, R.; Whiting, P.; McAllister, G.; Munoz-Sanjuan, I. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications Neuropsychopharmacology 2008, 33, 685-700
3. Chiarle, R.; Voena, C.; Ambrogio, C.; Piva, R.; Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer Nat. Rev. Cancer 2008, 8, 11-23
4. Webb, T. R.; Slavish, J.; George, R. E.; Look, A. T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W. B.; Morris, S. W. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy Expert Rev. Anticancer Ther. 2009, 9, 331-356
5. Iwahara, T.; Fujimoto, J.; Wen, D.; Cupples, R.; Bucay, N.; Arakawa, T.; Mori, S.; Ratzkin, B.; Yamamoto, T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system Oncogene 1997, 14, 439-449
6. Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K. G.; Shapiro, D. N.; Saltman, D. L.; Look, A. T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 1994, 263, 1281-1284
7. Yu, H.; Liu, X.; Li, H.; Shi, D.; Wang, C. ALK-positive large B-cell lymphoma: report of two cases and review of the literature J. Cancer Sci. Ther. 2011, 3, 228-232
8. Griffin, C. A.; Hawkins, A. L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E. J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors Cancer Res. 1999, 59, 2776-2780
9. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448, 561-566
10. Mano, H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer Cancer Sci. 2008, 99, 2349-2355
11. Shaw, A. T.; Solomon, B. Targeting anaplastic lymphoma kinase in lung cancer Clin. Cancer Res. 2011, 17, 2081-2086
12. Caren, H.; Abel, F.; Kogner, P.; Martinsson, I. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors Biochem. J. 2008, 416, 153-159
13. Mossé, Y. P.; Laudenslager, M.; Longo, L.; Cole, K. A; Wood, A.; Attiyeh, E. F.; Laquaglia, M. J.; Sennett, R.; Lynch, J. E.; Perri, P.; Laureys, G.; Speleman, F.; Kim, C.; Hou, C.; Hakonarson, H.; Torkamani, A.; Schork, N. J.; Brodeur, G. M.; Tonini, G. P.; Rappaport, E.; Devoto, M.; Maris, J. M. Identification of ALK as a major familial neuroblastoma predisposition gene Nature 2008, 455, 930-935
14. Janoueix-Lerosey, I.; Lequin, D.; Brugieres, L.; Ribeiro, A.; de Pontual, L.; Combaret, V.; Raynal, V.; Puisieux, A.; Schleiermacher, G.; Pierron, G.; Valteau-Couanet, D.; Frebourg, T.; Michon, J.; Lyonnet, S.; Amiel, J.; Delattre, O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma Nature 2008, 455, 967-970
15. Chen, Y.; Takita, J.; Choi, Y. L.; Kato, M.; Ohira, M.; Sanada, M.; Wang, Li.; Soda, M.; Kikuchi, A.; Igarashi, T.; Nakagawara, A.; Hayashi, Y.; Mano, H.; Ogawa, S. Oncogenic mutations of ALK kinase in neuroblastoma Nature 2008, 455, 971-974
16. George, R. E.; Sanda, T.; Hanna, M.; Frohling, S.; Luther, W., 2nd; Zhang, J.; Ahn, Y.; Zhou, W.; London, W. B.; McGrady, P.; Xue, L.; Zozulya, S.; Gregor, V.; Webb, T. R.; Nathanael, S.; Gray, N. S.; Gilliland, D. G.; Diller, L.; Greulich, H.; Stephan, W.; Morris, S. W.; Meyerson, M.; Look, A. T. Activating mutations in ALK provides a therapeutic target in neuroblastoma Nature 2008, 455, 975-978
17. Azarova, A. M.; Gautam, G.; George, R. E. Emerging importance of ALK in neuroblastoma Semin. Cancer Biol. 2011, 21, 267-275
18. Tuma, R. S. ALK gene amplified in most inflammatory breast cancers J. Natl. Cancer Inst. 2012, 104, 87-88
19. Ren, H.; Tan, X. Z.; Crosby, C.; Haack, H.; Ren, J.-M.; Beausoleil, S.; Moritz, A.; Innocenti, G.; Rush, J.; Zhang, Y.; Zhou, X.-M.; Gu, T.-L.; Yang, Y.-F.; Comb, M. J. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer Cancer Res. 2012, 72, 3312-3323
20. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P.-P.; Nambu, M. D.; Los, G.; Bender, B. L.; Mroczkowski, B.; Christensen, J. G. An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 2007, 67, 4408-4417
21. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G.; Mroczkowski, B.; Christensen, J. G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
22. Cui, J. J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P.-P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
23. TM (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment Annu. Rep. Med. Chem. 2013, 48, 421-432
24. Shaw, A. T.; Yeap, B. Y.; Solomon, B. J.; Riely, G. J.; Gainor, J.; Engelman, J. A.; Shapiro, G. I.; Costa, D. B.; Ou, S.-H. I.; Butaney, M.; Salgia, R.; Maki, R. G.; Varella-Garcia, M.; Doebele, R. C.; Bang, Y.-J.; Kulig, K.; Selaru, P.; Tang, Y.; Wilner, K. D.; Kwak, E. L.; Clark, J. W.; Iafrate, A. J.; Camidge, D. R. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol. 2011, 12, 1004-1012
25. Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; Ishikawa, Y.; Kimura, H.; Mitsudomi, T.; Tanio, Y.; Mano, H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med. 2010, 363, 1734-1739
26. Sasaki, T.; Okuda, K.; Zheng, W.; Butrynski, J.; Capelletti, M.; Wang, L.; Gray, N. S.; Wilner, K.; Christensen, J. G.; Demetri, G.; Shapiro, G. I.; Rodig, S. J.; Eck, M. J.; Jänne, P. A. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res. 2011, 71, 6051-6060
27. Zhang, S.; Wang, F.; Keats, J.; Zhu, X.; Ning, Y.; Wardwell, S. D.; Moran, L.; Mohemmad, Q. K.; Anjum, R.; Wang, Y.; Narasimhan, N. I.; Dalgarno, D.; Shakespeare, W. C.; Miret, J. J.; Clackson, T.; Rivera, V. M. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen Chem. Biol. Drug Des. 2011, 78, 999-1005
28. Doebele, R. C.; Pilling, A. B.; Aisner, D. L.; Kutateladze, T. G.; Le, A. T.; Weickhardt, A. J.; Kondo, K. L.; Linderman, D. J.; Heasley, L. E.; Franklin, W. A.; Varella-Garcia, M.; Camidge, D. R. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin. Cancer Res. 2012, 18, 1472-1482
29. Katayama, R.; Shaw, A. T.; Khan, T. M.; Mino-Kenudson, M.; Solomon, B. J.; Halmos, B.; Jessop, N. A.; Wain, J. C.; Yeo, A. T.; Benes, C.; Drew, L.; Saeh, J. C.; Crosby, K.; Sequist, L. V.; Iafrate, A. J.; Engelman, J. A. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancer Sci. Transl. Med. 2012, 4 120ra17
30. Kinoshita, K.; Oikawa, N.; Tsukuda, T. Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers Annu. Rep. Med. Chem. 2012, 47, 281-293
31. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275
32. Marsilje, T. H; Pei, W.; Chen, B.; Lu, W.; Uno, T.; Jin, Y.; Jiang, T.; Kim, S.; Li, N.; Warmuth, M.; Sarkisova, Y.; Sun, F.; Steffy, A.; Pferdekamper, A. C.; Li, A. G.; Joseph, S. B.; Kim, Y.; Liu, B.; Tuntland, T.; Cui, X.; Gray, N. S.; Steensma, R.; Wan, Y.; Jiang, J.; Chopiuk, G.; Li, J.; Gordon, W. P.; Richmond, W.; Johnson, K.; Chang, J.; Groessl, T.; He, Y.-Q.; Phimister, A.; Aycinena, A.; Lee, C. C.; Bursulaya, B.; Karanewsky, D. S.; Seidel, H. M.; Harris, J. L.; Michellys, P.-Y. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4- (2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J. Med. Chem. 2013, 56, 5675-5690
33. Kuromitsu, S.; Mori, M.; Shimada, I.; Kondoh, Y.; Shindoh, N.; Soga, T.; Furutani, T.; Konagai, S.; Sakagami, H.; Nakata, M.; Ueno, Y.; Saito, R.; Sasamata, M.; Kudou, M. Anti-tumor activity of ASP3026, a novel and selective ALK inhibitor of anaplastic lymphoma kinase (ALK). Presented at the Annual Meeting of the American Association for Cancer Research (AACR), Orlando, FL, 2011; Abstract 2821.
34. Sakamoto, H.; Tsukaguchi, T.; Hiroshima, S.; Kodama, T.; Kobayashi, T.; Fukami, T. A.; Oikawa, N.; Tsukuda, T.; Ishii, N.; Aoki, Y. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 2011, 19, 679-690
35. Kinoshita, K.; Kobayashi, T.; Asoh, K.; Furuichi, N.; Ito, T.; Kawada, H.; Hara, S.; Ohwada, J.; Hattori, K.; Miyagi, T.; Hong, W.-S.; Park, M.-J.; Takanashi, K.; Tsukaguchi, T.; Sakamoto, H.; Tsukuda, T.; Oikawa, N. 9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors J. Med. Chem. 2011, 54, 6286-6294
36. Katayama, R.; Khan, T. M.; Benes, C.; Lifshits, E.; Eb, H.; River, V. M.; Shakespeare, W. C.; Iafrate, A. J.; Jeffrey, A.; Engelman, J. A.; Shaw, A. T. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 7535-7540
37. Edwards, M. P.; Price, D. A. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks Annu. Rep. Med. Chem. 2010, 45, 381-391
38. Freeman-cook, K. D.; Hoffman, R. L.; Johnson, T. W. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry Future Med. Chem. 2013, 5, 113-115
39. Crizotinib has an extensive tumor distribution profiles with an approximate tumor/plasma AUC ratio of 4 at steady-state (in-house data). Also see Yamazaki, S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib AAPS J. 2013, 15, 354-366
40. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds J. Med. Chem. 2001, 44, 2490-2497
41. Hosea, N. A.; Collard, W. T.; Cole, S.; Maurer, T. S.; Fang, R. X.; Jones, H.; Kakar, S. M.; Nakai, Y.; Smith, B. J.; Webster, R.; Beaumont, K. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches J. Clin. Pharmacol. 2009, 49, 513-533
42. Di, L.; Whitney, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a new permeability assay using low-efflux MDCKII cells J. Pharm. Sci. 2011, 100, 4974-4985
43. Nishio, M.; Hirota, M.; Umezawa, Y., Eds. The CH-Pi Interaction: Evidence, Nature, and Consequences; Wiley-VCH: New York, 1998; pp 1-215.
44. Nishio, M. CH/π hydrogen bonds in crystals CrystEngComm 2004, 6, 130-158
45. Gainor, J. F.; Shaw, A. T. Novel target in non-small cell lung cancer: ROS1 and RET fusions Oncologist 2013, 18, 865-875
46. Chin, L. P.; Soo, R. A.; Soong, R.; Ou, S. H. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer J. Thorac. Oncol. 2012, 7, 1625-1630
47. Brown, H. C.; Chandrasekharan, J.; Ramachandran, P. V. Chiral synthesis via organoboranes. 14. Selective reductions. 41. Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent J. Am. Chem. Soc. 1988, 110, 1539-1546
48. Ramachandran, P. V.; Gong, B.; Brown, H. C. A remarkable inversion in configuration of the product alcohols from the asymmetric reduction of ortho -hydroxyacetophenones with β-chlorodiisopinocampheylborane Tetrahedron Lett. 1994, 35, 2141-2144
49. Kolb, H. C.; Van Nieuwenhze, M. S.; Sharpless, K. B. Catalytic asymmetric dihydroxylation Chem. Rev. 1994, 94, 2483-2547
50. Noe, M. C.; Letavic, M. A.; Snow, S. L. Asymmetric dihydroxylation of alkenes Org. React. 2005, 66, 109